Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02470507
Other study ID # CSP88220
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date June 2013
Est. completion date December 1, 2026

Study information

Verified date January 2024
Source Guy's and St Thomas' NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The immune response to kidney damage during acute kidney injury (AKI) is an important contributor to the prolonged lack of renal function and progression of kidney injury. Most data related to intrarenal and interorgan pathways in AKI stem from animal research with sometimes conflicting results. Accurate evaluation of these processes in humans and identification of early diagnostic tools are critical for the development of strategies to prevent and attenuate AKI-related morbidity and mortality in patients. The aim of this study is to evaluate immune function and miRNA expression in hospitalised patients with and without AKI.


Description:

Hypothesis: An overriding pro-inflammatory immune response underlies AKI in humans which contributes to dysfunction of non-renal organs Principal research question: Is AKI in humans associated with a predominantly pro-inflammatory immune response? Secondary research questions: 1. Does AKI affect the phenotypic characterisation and function of neutrophils? 2. Does severity of AKI lead to differences in phenotypic characterisation and function of neutrophils? 3. What are the differences in cytokine profiles between AKI patients with and without systemic inflammation? 4. What are the differences in cytokine profiles between AKI patients with systemic inflammation and patients with systemic inflammation without AKI? 5. Is there a correlation between microRNA levels in patients with AKI and degree of AKI, renal recovery and patient outcome? Study design: Observational non-interventional study Study population: 30 patients with AKI stage II or III * and systemic inflammation without sepsis 30 patients with AKI stage II or III * and no systemic inflammation 30 patients with systemic inflammation and normal renal function 30 patients after major surgery who do not have an infection, SIRS or AKI * AKI will be defined by the KDIGO criteria Primary outcome Detection of measurable phenotypic characteristics and function of leukocytes that are specific of patients with AKI. Secondary outcomes: 1. Differences in phenotypic characterisation and function of neutrophils between patients with AKI stage II and III. 2. Differences in phenotypic characterisation and function of neutrophils between patients with and without AKI. 3. Differences in cytokine profiles between patients with AKI and systemic inflammation and patients with AKI without systemic inflammation 4. Differences in cytokine profiles between AKI patients with systemic inflammation and patients with systemic inflammation without AKI 5. Correlation between microRNA levels in patients with AKI and renal recovery 6. Correlation between microRNA levels in patients with AKI and patient outcome 7. Differences in cytokine profiles between AKI patients without systemic inflammation and patients without AKI and without systemic inflammation / infection. Statistical analysis: For the analysis of laboratory variables that describe the immunological phenotype, standard statistical methods will be applied. 1) When the normal distribution assumption is met, groups will be compared using ANOVA and the corresponding contrasts for group by group comparisons; 2) In the absence of normality or for ordinal variables, Kruskal Wallis will be applied for multi-group comparisons, and Wilcoxon for two-groups analysis. We will apply multiple testing correction via Benjamini-Hochberg FDR control. For the analysis of miRNA array data, we will first follow the protocol quality control measures appropriate for the platform of choice, and subsequently will carry out statistical analysis using the SAMr and LIMMA packages from Bioconductor, via the R software. Similarly, for the analysis of PCR data, the package HTqPCR from bioconductor will be used for quality control. Depending on the distribution of the final data, either non-parametric statistics, or a moderated t-test will be applied for statistical comparisons, with the corresponding multiple testing corrections as above.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date December 1, 2026
Est. primary completion date August 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (= 18 years) admitted to the hospital (incl ICU) with one of the following: 1. postoperative AKI II or III and systemic inflammation without sepsis 2. systemic inflammation and normal renal function 3. AKI II or III without systemic inflammation 4. post-surgery with normal renal function and without SIRS or an infection Exclusion Criteria: - Renal transplant patients - Patients on immunosuppressive drugs (except steroids) - Patients with haematological malignancy - Jehovah's witness

Study Design


Intervention

Other:
AKI
development of immune dysregulation and rise in inflammatory markers and activation of immune cells

Locations

Country Name City State
United Kingdom Guy's & St Thomas Foundation Hospital London

Sponsors (2)

Lead Sponsor Collaborator
Guy's and St Thomas' NHS Foundation Trust King's College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phenotypic characteristics and function of leukocytes 7 days
Secondary Differences in phenotypic characterisation and function of neutrophils between AKI stage II and III. 7 days
Secondary Differences in phenotypic characterisation and function of neutrophils between AKI and no AKI 7 days
Secondary Differences in cytokine profiles between AKI + SIRS and AKI without SIRS 7 days
Secondary Differences in cytokine profiles between SIRS + AKI and SIRS without AKI 7 days
Secondary Correlation between microRNA levels in patients with AKI and renal recovery Correlation between microRNA levels in patients with AKI and patient outcome Differences in cytokine profiles between AKI patients without systemic inflammation and patients without AKI and without systemic inflammation / infection. 7 days
Secondary Correlation between microRNA levels in patients with AKI and patient outcome Differences in cytokine profiles between AKI patients without systemic inflammation and patients without AKI and without systemic inflammation / infection. 7 days
Secondary Differences in cytokine profiles between AKI patients without SIRS and patients without AKI and without SIRS 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT00760591 - Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study) N/A
Completed NCT00890214 - Prostacyclin's Effect on Platelet Responsiveness Phase 4
Active, not recruiting NCT03675906 - The Relationship Between Hypoalbuminemia and Development of Acute Kidney Failure (AKI) According to KDIGO Criteria
Recruiting NCT04334707 - Kidney Precision Medicine Project
Active, not recruiting NCT04079829 - Postoperative Respiratory Abnormalities
Recruiting NCT00424320 - Clinical Trial of Sodium Bicarbonate to Prevent Contrast-Induced Nephropathy Phase 3
Completed NCT00472563 - Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate Phase 2/Phase 3
Withdrawn NCT03846258 - High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy Phase 4
Completed NCT06358365 - Enhancing Fluid Transfer Through the Skin, by Increased Sweat Rate, on Hemodialysis Patients N/A
Completed NCT00252200 - BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery. Phase 1/Phase 2
Completed NCT04190979 - Clinical Application of the Medyria TrackCath System in Endovascular Repair of Abdominal Aortic Aneurysms (AAA) N/A
Completed NCT04917497 - Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
Recruiting NCT05309291 - Theranova Randomized, Controlled, Trial (RCT) in China N/A
Completed NCT02486614 - Effect of Citrate on the Coagulation System in Patients Receiving CRRT
Active, not recruiting NCT05384899 - Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol
Completed NCT06190522 - Diagnosis of Acute Obstructive Renal Failure by Clinical Ultrasound Performed by the Emergency Physician.
Recruiting NCT04221932 - Implementation of CRRT KPI Reports to Standardize and Improve the Quality of CRRT Delivery in Alberta "QUALITY CRRT"
Active, not recruiting NCT01122225 - Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury N/A
Completed NCT00529139 - Hannover Dialysis Outcome Study Phase 4
Recruiting NCT04445779 - Q10 Preloading Before Cardiac Surgery for Kidney Failure Reduction N/A